旅行疫苗市場 - 全球產業規模、佔有率、趨勢、機會及預測（依成分、疾病、旅遊類型、地區及競爭格局分類，2021-2031年）

全球旅行疫苗市場預計將從 2025 年的 68.1 億美元成長到 2031 年的 115.6 億美元，複合年成長率達到 9.22%。

旅行疫苗是旨在為前往特定地區的旅行者提供針對當地性行為感染的獲得性免疫的生物製藥。市場成長的主要驅動力是國際觀光的強勁復甦以及各國政府嚴格的簽證簽發強制接種疫苗規定。全球可支配收入的成長進一步推動了這一擴張，促進了跨境旅行和商務旅行。聯合國世界旅遊組織的數據顯示，到2024年，國際觀光人數將恢復到疫情前水準的96%，這預示著全球流動性的強勁復甦，而這直接推動了對醫療保健措施的需求。

儘管成長指標積極，但疫苗市場仍面臨與疫苗分銷複雜物流相關的重大障礙。嚴格的低溫運輸儲存要求導致營運成本高昂，並造成分銷效率低下，尤其是在基礎設施薄弱的開發中國家。因此，這些供應鏈限制構成重大挑戰，可能限制基本免疫接種的廣泛普及，並阻礙全球旅行疫苗產業的整體擴張。

市場促進因素

全球國際觀光和商務旅行的復甦將是推動市場擴張的關鍵因素。人員流動增加將直接轉化為疫苗接種量的提升。隨著航空網路的改善和邊境的全面開放，旅客將擴大前往地方性疾病肆虐的偏遠和熱帶地區，這些地區存在嚴重的健康風險，因此接種疫苗至關重要。這種人員流動增加的趨勢將確保旅行者健康診所和製藥企業擁有穩定的患者群體，尤其是甲型肝炎、傷寒和黃熱病疫苗。國際航空運輸協會（IATA）2024年7月發布的《航空旅客市場分析報告》也印證了這一復甦趨勢：2024年5月國際旅客需求同比成長14.6%，凸顯了跨境旅行的快速復甦對市場需求的支撐作用。

同時，熱門旅遊目的地新興和再發感染疾病的日益普及促使旅客在出發前接種疫苗。熱帶地區蟲媒感染疾病的爆發加劇了遊客和外籍人士採取預防措施的緊迫性，並推動了新核准疫苗的普及。例如，登革熱傳播的顯著擴大導致對預防方案的需求迅速成長。根據美洲衛生組織（PAHO）2024年3月發布的《登革熱流行病學最新情況》，到2024年初，美洲將確診超過350萬例疑似登革熱病例，與歷史平均水準相比，增幅驚人。這種流行病學情勢為疫苗研發商帶來了切實的經濟效益。巴伐利亞北歐公司（Bavarian Nordic）公佈，其2023年全年旅遊健康部門的收入為18.77億丹麥克朗，這表明高感染風險帶來了顯著的商業性影響。

市場挑戰

複雜的物流和嚴格的低溫運輸儲存要求對全球旅行疫苗市場的成長構成了重大障礙。旅行疫苗屬於生物製藥，通常需要在整個運輸過程中進行精確的溫度控制，從冷藏到超低溫不等。在基礎設施低度開發的地區，維持這種溫度連續性不僅在操作上具有挑戰性，而且在經濟上也負擔沉重。由此導致的高昂營運成本和產品劣化風險增加，阻礙了生產商和經銷商有效率地進入這些市場。因此，這種物流方面的脆弱性有效地限制了收入潛力，因為該行業正努力確保在最需要的地區提供必要的疫苗。

由於必須透過受限的供應鏈網路運輸大量產品，營運負擔進一步加重。運送大量對溫度敏感的管瓶的壓力加劇了現有分銷效率低下的問題。根據聯合國兒童基金會2024年年度供應報告，該組織在2024年向99個國家分發了27.87億劑疫苗。透過脆弱的低溫運輸處理如此龐大的數量，不可避免地會導致瓶頸和供應中斷。這些限制直接限制了市場覆蓋範圍，並削弱了該行業充分利用全球旅遊業復甦帶來的醫療保健需求成長的能力。

市場趨勢

針對媒介傳播疾病的新型疫苗的商業化，正推動市場從研發階段轉向已通過核准的、用於預防被忽視的熱帶疾病的藥物供應階段。研發人員正推動法規核准流程，並將針對屈公病等疾病的疫苗推向市場，填補了前往流行地區旅客預防保健方面的空白。這種從開發平臺到商業化的轉變，能夠即時創造商業性價值，並促進旅行健康產品組合擴展到傳統疫苗之外。根據巴伐利亞北歐公司（Bavarian Nordic A/S）於2025年11月發布的“2025年前第一季季度中期財務業績”，其旅行健康業務的收入成長了23%，達到23.27億丹麥克朗。這一成長勢頭得益於該公司基孔肯雅疫苗Vimkunya的商業性化上市。

同時，多價疫苗和結合疫苗製劑的研發正在重塑疫苗接種策略，單一產品即可提供廣譜保護。與單價疫苗相比，四價疫苗（可同時針對多種病毒血清型進行免疫）技術簡化了接種流程，提高了旅客的依從性，因此，生產商正優先研發此類技術。這項創新透過減輕旅遊醫療保健機構的後勤負擔，改善了臨床療效並加速了市場滲透。根據武田藥品工業株式會社於2025年1月發布的“2024會計年度第三季度財務業績”，該公司四價登革熱疫苗“Qdenga”上半年銷售額達199億日元，較去年同期成長863%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球旅行疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依成分（單藥疫苗與合併疫苗）
  • 依疾病分類（甲型肝炎、百白破疫苗、黃熱病、傷寒、B型肝炎、麻疹/腮腺炎、狂犬病、腦膜炎雙球菌病、水痘、日本腦炎、其他）
  • 依旅行類型（國內旅行與國際旅行）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美旅行疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲旅行疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區旅行疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲旅行疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲旅行疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球旅行疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GlaxoSmithKline, plc
• Sanofi SA
• Novartis International AG
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc
• Abbott Laboratories, Inc
• F. Hoffmann-La Roche AG
• CSL Limited
• Johnson & Johnson

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Travel Vaccine Market is projected to expand from USD 6.81 Billion in 2025 to USD 11.56 Billion by 2031, achieving a CAGR of 9.22%. Travel vaccines are biological preparations designed to provide acquired immunity against endemic infectious diseases for individuals traveling to specific regions. The market's growth is primarily fueled by the strong recovery of international tourism and stringent government mandates that require immunization for visa approvals. This expansion is further bolstered by rising global disposable incomes, which enable greater cross-border mobility and business travel. UN Tourism data indicates that in 2024, international tourist arrivals recovered to 96 percent of pre-pandemic levels within the first seven months, signaling a robust resurgence in global movement that directly drives the demand for prophylactic healthcare measures.

Despite these favorable growth indicators, the market encounters significant obstacles related to the complex logistics required for vaccine distribution. Stringent cold chain storage necessities impose high operational costs and create distribution inefficiencies, particularly in developing nations that lack robust infrastructure. Consequently, these supply chain constraints constitute a substantial challenge that could limit the widespread accessibility of essential immunizations and hinder the overall expansion of the global travel vaccine sector.

Market Driver

The revival of global international tourism and business travel serves as a major catalyst for market expansion, as heightened mobility directly leads to increased vaccine administration. As air connectivity improves and borders fully reopen, travelers are increasingly visiting exotic and tropical locations where endemic diseases present significant health risks, necessitating prophylactic immunization. This upward trend in mobility secures a sustained patient base for travel medicine clinics and pharmaceutical manufacturers, particularly for vaccines protecting against hepatitis A, typhoid, and yellow fever. Highlighting this recovery, the International Air Transport Association's 'Air Passenger Market Analysis' from July 2024 noted that total international passenger demand increased by 14.6 percent in May 2024 compared to the previous year, underscoring the rapid restoration of cross-border movement that supports market demand.

Simultaneously, the rising prevalence of emerging and re-emerging infectious diseases in popular tourist destinations compels travelers to obtain vaccinations before departure. Outbreaks of vector-borne illnesses in tropical regions have increased the urgency for preventative measures among tourists and business expatriates, driving the adoption of newly approved immunization options. For example, the significant expansion of dengue fever transmission zones has created an acute demand for preventative solutions. The Pan American Health Organization reported in its March 2024 'Epidemiological Update Dengue' that the Americas region saw over 3.5 million suspected dengue cases in early 2024, a staggering rise compared to historical averages. This epidemiological landscape generates tangible financial gains for vaccine developers; Bavarian Nordic reported that its Travel Health segment achieved revenues of DKK 1,877 million for the full year of 2023, reflecting the robust commercial impact of high infection risks.

Market Challenge

Complex logistics and stringent cold chain storage requirements act as a formidable barrier to the growth of the Global Travel Vaccine Market. Travel vaccines are biological products that typically require precise temperature controls, ranging from refrigerated to cryogenic states, throughout their entire transit. in regions with underdeveloped infrastructure, maintaining this thermal continuity is both operationally difficult and financially burdensome. The resulting high operational costs and elevated risks of product spoilage deter manufacturers and distributors from efficiently expanding into these markets. Consequently, this logistical fragility effectively places a ceiling on revenue potential, as the industry struggles to guarantee the reliable availability of essential immunizations in destinations where they are most needed.

This operational strain is further intensified by the immense volume of products that must navigate these often-constrained supply networks. The pressure to transport vast quantities of temperature-sensitive vials amplifies existing distribution inefficiencies. According to UNICEF's Supply Annual Report 2024, the organization managed the international delivery of 2.787 billion vaccine doses to 99 countries in 2024. Processing such a massive volume through fragile cold chains inevitably leads to bottlenecks and supply interruptions. These constraints directly restrict market reach and undermine the industry's capacity to fully capitalize on the heightened demand for prophylactic healthcare driven by the resurgence of global tourism.

Market Trends

The commercialization of novel vaccines for vector-borne diseases is shifting the market from research to the availability of approved prophylactics for neglected tropical illnesses. Developers are navigating regulatory pathways to launch immunizations for diseases like chikungunya, filling the preventative care gap for travelers visiting endemic regions. This transition from pipeline to product generates immediate commercial value and expands the travel health portfolio beyond traditional vaccines. According to Bavarian Nordic A/S, in its November 2025 'Interim Results for the First Nine Months of 2025', Travel Health revenue increased by 23 percent to DKK 2,327 million, a growth trajectory supported by the commercial launch of its chikungunya vaccine, Vimkunya.

Concurrently, the development of multivalent and combination vaccine formulations is reshaping immunization strategies by offering broad-spectrum protection through single-product solutions. Manufacturers are prioritizing tetravalent technologies that induce immunity against multiple virus serotypes simultaneously, simplifying vaccination schedules and enhancing traveler compliance compared to monovalent alternatives. This innovation improves clinical outcomes and drives market uptake by streamlining the logistical burden for travel medicine providers. According to Takeda Pharmaceutical Company Limited's January 2025 'earnings results for the third quarter of fiscal year 2024', the company reported that its tetravalent dengue vaccine, Qdenga, generated 19.9 billion JPY in revenue for the first half of the fiscal year, marking an 863 percent increase.

Key Market Players

• GlaxoSmithKline, plc
• Sanofi S.A.
• Novartis International AG
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc
• Abbott Laboratories, Inc
• F. Hoffmann-La Roche AG
• CSL Limited
• Johnson & Johnson

Report Scope

In this report, the Global Travel Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Travel Vaccine Market, By Composition

• Mono Vaccines v/s Combination Vaccines

Travel Vaccine Market, By Disease Indication

• Hepatitis A
• DPT
• Yellow Fever
• Typhoid
• Hepatitis B
• Measles and Mumps
• Rabies
• Meningococcal
• Varicella
• Japanese Encephalitis
• Others

Travel Vaccine Market, By Travel Type

• Domestic v/s International

Travel Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Travel Vaccine Market.

Available Customizations:

Global Travel Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Travel Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Composition (Mono Vaccines v/s Combination Vaccines)
  • 5.2.2. By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others)
  • 5.2.3. By Travel Type (Domestic v/s International)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Travel Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Composition
  • 6.2.2. By Disease Indication
  • 6.2.3. By Travel Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Travel Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Composition
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By Travel Type
  • 6.3.2. Canada Travel Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Composition
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By Travel Type
  • 6.3.3. Mexico Travel Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Composition
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By Travel Type

7. Europe Travel Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Composition
  • 7.2.2. By Disease Indication
  • 7.2.3. By Travel Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Travel Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Composition
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Travel Type
  • 7.3.2. France Travel Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Composition
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Travel Type
  • 7.3.3. United Kingdom Travel Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Composition
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Travel Type
  • 7.3.4. Italy Travel Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Composition
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By Travel Type
  • 7.3.5. Spain Travel Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Composition
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By Travel Type

8. Asia Pacific Travel Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Composition
  • 8.2.2. By Disease Indication
  • 8.2.3. By Travel Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Travel Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Composition
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Travel Type
  • 8.3.2. India Travel Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Composition
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Travel Type
  • 8.3.3. Japan Travel Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Composition
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Travel Type
  • 8.3.4. South Korea Travel Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Composition
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Travel Type
  • 8.3.5. Australia Travel Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Composition
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Travel Type

9. Middle East & Africa Travel Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Composition
  • 9.2.2. By Disease Indication
  • 9.2.3. By Travel Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Travel Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Composition
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Travel Type
  • 9.3.2. UAE Travel Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Composition
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Travel Type
  • 9.3.3. South Africa Travel Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Composition
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Travel Type

10. South America Travel Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Composition
  • 10.2.2. By Disease Indication
  • 10.2.3. By Travel Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Travel Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Composition
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Travel Type
  • 10.3.2. Colombia Travel Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Composition
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Travel Type
  • 10.3.3. Argentina Travel Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Composition
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Travel Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Travel Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GlaxoSmithKline, plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi S.A.
• 15.3. Novartis International AG
• 15.4. Merck KGaA
• 15.5. Pfizer Inc.
• 15.6. AstraZeneca Plc
• 15.7. Abbott Laboratories, Inc
• 15.8. F. Hoffmann-La Roche AG
• 15.9. CSL Limited
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer